Does the presence of hepatitis virus B and C influence the evolution of diffuse large B-cell lymphoma?

References

• Swerdlow SH, Campo E, Harris NL, et al, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
   Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268–276.
   PubMed Web of Science ®Google Scholar
• Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol 2010;11:827–834.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, García-Buey L, Pajares JM, et al. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology 2003;125: 1723–1732.
   PubMed Web of Science ®Google Scholar
• Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multi-center case-control study. Blood 2003;102:996–999.
   PubMed Web of Science ®Google Scholar
• Luppi M, Longo G, Ferrari MG, et al. Additional neoplasms and HCV infection in low-grade lymphoma of MALT type. Br J Haematol 1996;94:373–375.
   PubMed Web of Science ®Google Scholar
• De Vita S, Sacco C, Sansonno D, et al. Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. Blood 1997;90:776–782.
   PubMed Web of Science ®Google Scholar
• Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992;327: 1490–1495.
   PubMed Web of Science ®Google Scholar
• Andreone P, Gramenzi A, Cursaro C, et al. Monoclonal gammopathy in patients with chronic hepatitis C virus infection. Blood 1996;88:1122.
   PubMed Web of Science ®Google Scholar
• Ferri C, Caracciolo F, Zignego AL, et al. Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Br J Haematol 1994;88:392–394.
   PubMed Web of Science ®Google Scholar
• Germanidis G, Haioun C, Dhumeaux D, et al. Hepatitis C virus infection, mixed cryoglobulinemia, and B-cell non-Hodgkin's lymphoma. Hepatology 1999;30:822–823.
   PubMed Web of Science ®Google Scholar
• Cvetkovic RS, Perry CM. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2006;66:791–820.
   PubMed Web of Science ®Google Scholar
• Perceau G, Diris N, Estines O, et al. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006;155:1053–1056.
   PubMed Web of Science ®Google Scholar
• Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;344:68–69.
   PubMed Web of Science ®Google Scholar
• Sera T, Hiasa Y, Michitaka K, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006;45:721–724.
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Kawamura T, Saitoh S, et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004;45: 627–629.
   PubMed Web of Science ®Google Scholar
• Kusumoto S, Tanaka Y, Mizokami M, et al. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009;90:13–23.
   PubMed Web of Science ®Google Scholar
• Westhoff TH, Jochimsen F, Schmittel A, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003;102:1930.
   PubMed Web of Science ®Google Scholar
• Law JK, Ho JK, Hoskins PJ, et al. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005;46:1085–1089.
   PubMed Web of Science ®Google Scholar
• IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 2012;100:1–441.
   Google Scholar
• Suarez F, Lortholary O, Hermine O, et al. Infection associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 2006;107:3034–3044.
   PubMed Web of Science ®Google Scholar
• Besson C, Canioni D, Lepage E, et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d’Etude des Lymphomes del’Adulte Programs. J Clin Oncol 2006;24:953–960.
   PubMed Web of Science ®Google Scholar
• Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97–107.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan P, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299–307.
   PubMed Web of Science ®Google Scholar
• Hoofnagle J. Reactivation of Hepatitis B. Hepatology 2009; 49(Suppl. 5):S156–S165.
   Google Scholar
• Sanchez MJ, Buti M, Homs M, et al. Successful use of entecavir for a severe a case of reactivation of hepatits B virus following polychemotherapy containing rituximab. J Hepatol 2009;51:1091–1096.
   PubMed Web of Science ®Google Scholar
• Colson P, Borentain P, Cose D, et al. Entecavir as a first line treatment for HBV reactivation following polychemotherapy for lymphoma. Br J Haematol 2008;143:148–150.
   PubMed Web of Science ®Google Scholar
• Mahale P, Kontoyiannis DP, Chemaly RF, et al. Acute exacerbation and viral reactivation of chronic hepatitis C infection in cancer patients. J Hepatol 2012;57:1177–1185.
   PubMed Web of Science ®Google Scholar
• Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 2012;9:156–166.
   PubMed Web of Science ®Google Scholar
• Mahale P, Okhuysen PC, Torres HA. Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals? Clin Gastroenterol Hepatol 2014;12:1051–1054.e1
   PubMed Web of Science ®Google Scholar